CAS: 269409-99-6; Ethyl 2-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)Benzoate

上下游产品

benzoic acid ethyl ester 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 2,3-dimethyl-2,3-butane diol ethyl 2-iodobenzoate 2,3-diphenyl-1H-inden-1-one ethyl 2-(4-chloro-1,3-thiazol-2-yl)benzoate 2-[2-amino-4-(1,3-dihydroisoindole-2-carbonyl)quinazolin-6-yl]benzoic acid 2-(2-aminoquinolin-6-yl)benzoic acid

📜苯甲酸置于5-甲基-2-(噻吩-3-基)吡啶,(1,5-Cyclooctadiene)(Methoxy)Iridium(I) Dimer,硫酸体系中,用 甲基叔丁基醚 用作溶剂,化学反应 36.03H,反应生成2-乙氧羰基苯硼酸频哪醇酯
参考文献:用于定向 C(Sp2)-h 和 C(Sp3)-h 硼酸化不同类型底物的显着高效铱催化剂
标题:用于定向 C(Sp2)-h 和 C(Sp3)-h 硼酸化不同类型底物的显着高效铱催化剂
摘要:在这里,我们描述了一类新的 C-H 硼化催化剂的发现及其在芳族,杂芳族和脂肪族系统的区域选择性 C-H 硼化中的应用.新催化剂具有 Ir-C(噻吩基) 或 Ir-C(呋喃基) 阴离子配体,而不是标准 C-H 硼化条件中使用的二胺型中性螯合配体.据报道,这些新发现的催化剂的使用对不同种类的芳烃底物显示出优异的反应性和邻位选择性,并具有高分离产率.此外,该催化剂被证明对大量脂肪族底物的选择性 C(Sp 3)-h 键硼化.杂环分子利用 C-H 键固有的高反应性选择性地硼化.已经使用相同的催化剂描述了许多后期 C-H 功能化.此外,我们表明其中一种催化剂甚至可以在露天用于 C(Sp 2 )-H 和 C(Sp 3 )-H 硼酸化,从而使该方法更加通用.初期机理研究表明,活性催化中间体是 Ir(Bis)Boryl 络合物,连接的配体作为双齿配体.总的来说,这项研究强调了新型 C-H 硼酸化催化剂的发现,这些催化剂应该在
Doi:10.1021/jacs.0C13415

专利信息

专利号:US-7122694-B2
优先权日:1998-11-06
标 题 :Hydroboronation process
发明人：MARCUCCIO SEBASTIAN MARIO; RODOPOULOS MARY; WEIGOLD HELMUT
权利人:BORON MOLECULAR PTY LTD
摘要:The invention relates to processes for the synthesis of aryl or alkene borates which comprises reacting: (i) an olefinic compound having a halogen or halogen-like substituent in a vinylic substitution position, or (ii) an aromatic ring having a halogen or halogen-like substituent in a ring substitution position, with a disubstituted monohydroborane in the presence of a Group 8-11 metal catalyst. The invention also relates to the use of these borates in coupling reactions. The invention further relates to certain disubstituted monohydroboranes and aryl or alkene borates.

专利号:US-10017481-B2
优先权日:2012-03-17
标 题 :Conformationally constrained, fully synthetic macrocyclic compounds
发明人：OBRECHT DANIEL; ERMERT PHILIPP; OUMOUCH SAID; PIETTRE ARNAUD; GOSALBES JEAN-FRANÇOIS; THOMMEN MARC
权利人:POLYPHOR AG
摘要:The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.